Abstract 252P
Background
RCC accounts for nearly 4% of all malignancies, in the Philippines, RCC ranks as the 15th most common cancer in 2018. The National Kidney and Transplant institute Cancer registry ranks RCC as the institute’s 4th most common malignancy at 10%. Studies to improve the diagnostic work up and follow up of this rare malignancy but apparently common in this institution can contribute for a better management and characterization of RCC.
Methods
This is a retrospective cohort study which included all patients who underwent nephrectomy for localized renal cell cancer from January 2017 to December 2021.
Results
There were 464 eligible patients included in this study. Clinical factors associated with recurrence of RCC upon multivariate analysis are bilateral sidedness, pT2 and beyond, WHO Grade 3-4, tumor encompassing the entire kidney, sarcomatoid and rhabdoid features, tumor necrosis, tumor thrombus, lymphovascular space invasion and positive surgical margins. Most common sites of recurrence was lungs (58.33%) followed by lymph nodes (45.83%) then bones (20.83%).
Conclusions
Presence of poor prognostic factors as well as positive lymph nodes are highly associated with local and distant RCC recurrence. A more stringent follow up with appropriate imaging may allow early intervention of metastatic diseases and possible consideration of lymph node dissection may improve recurrence free survival.
Clinical trial identification
Editorial acknowledgement
101 Health research.
Legal entity responsible for the study
The author.
Funding
National Kidney and Transplant Institute.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract